The University of Chicago Header Logo

Connection

Randy Sweis to Humans

Back to Details
This is a "connection" page, showing publications Randy Sweis has written about Humans.
Randy Sweis
Connection Strength
0.548
Humans
  1. STING activators in cancer care. Clin Adv Hematol Oncol. 2024 Sep; 22(7):331-333.
    View in: PubMed
    Score: 0.032
  2. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy. Curr Oncol Rep. 2023 03; 25(3):189-199.
    View in: PubMed
    Score: 0.028
  3. Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival. Sci Rep. 2021 05 11; 11(1):9983.
    View in: PubMed
    Score: 0.025
  4. FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer. Front Immunol. 2020; 11:575258.
    View in: PubMed
    Score: 0.024
  5. The Tumor Microenvironment of Bladder Cancer. Adv Exp Med Biol. 2020; 1296:275-290.
    View in: PubMed
    Score: 0.023
  6. Methods to assess anticancer immune responses in orthotopic bladder carcinomas. Methods Enzymol. 2020; 635:127-137.
    View in: PubMed
    Score: 0.023
  7. Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer. JAMA Oncol. 2019 05 01; 5(5):743.
    View in: PubMed
    Score: 0.022
  8. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019 03 11; 7(1):66.
    View in: PubMed
    Score: 0.022
  9. Low clinical adoption of tumor genomic profiling: cause for concern? J Med Econ. 2018 Jul; 21(7):721-723.
    View in: PubMed
    Score: 0.020
  10. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer. 2018 04 04; 6(1):24.
    View in: PubMed
    Score: 0.020
  11. Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol Res. 2017 Jun; 120:1-9.
    View in: PubMed
    Score: 0.019
  12. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Urol Oncol. 2016 12; 34(12):556-565.
    View in: PubMed
    Score: 0.018
  13. Obviating the Need for Serial Biopsies Through Random Assignment. J Clin Oncol. 2017 01 10; 35(2):260.
    View in: PubMed
    Score: 0.018
  14. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
    View in: PubMed
    Score: 0.018
  15. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8.
    View in: PubMed
    Score: 0.018
  16. Reply to T.A. Yap et al. J Clin Oncol. 2016 07 10; 34(20):2432-3.
    View in: PubMed
    Score: 0.018
  17. Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. J Clin Oncol. 2016 Feb 01; 34(4):369-74.
    View in: PubMed
    Score: 0.017
  18. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients. Aliment Pharmacol Ther. 2013 Jun; 37(11):1093-102.
    View in: PubMed
    Score: 0.014
  19. Actinomyces-induced inflammatory pseudotumor of the lymph node mimicking scrofula. Ann Intern Med. 2011 Jul 05; 155(1):66-7.
    View in: PubMed
    Score: 0.013
  20. A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392.
    View in: PubMed
    Score: 0.008
  21. Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Rep. 2024 May 28; 43(5):114141.
    View in: PubMed
    Score: 0.008
  22. Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model. Front Immunol. 2024; 15:1358019.
    View in: PubMed
    Score: 0.008
  23. A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma. Invest New Drugs. 2024 Apr; 42(2):179-184.
    View in: PubMed
    Score: 0.008
  24. NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024 02; 22(1):4-16.
    View in: PubMed
    Score: 0.008
  25. Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
    View in: PubMed
    Score: 0.008
  26. Melanoma and microbiota: Current understanding and future directions. Cancer Cell. 2024 01 08; 42(1):16-34.
    View in: PubMed
    Score: 0.008
  27. Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms. Sci Rep. 2023 12 18; 13(1):22541.
    View in: PubMed
    Score: 0.008
  28. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma. Eur Urol Oncol. 2024 Aug; 7(4):933-943.
    View in: PubMed
    Score: 0.008
  29. Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. Clin Cancer Res. 2023 01 04; 29(1):110-121.
    View in: PubMed
    Score: 0.007
  30. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
    View in: PubMed
    Score: 0.007
  31. Hallmarks of Resistance to Immune-Checkpoint Inhibitors. Cancer Immunol Res. 2022 04 01; 10(4):372-383.
    View in: PubMed
    Score: 0.007
  32. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2022 02 15; 28(4):677-688.
    View in: PubMed
    Score: 0.007
  33. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021 07; 22(7):946-958.
    View in: PubMed
    Score: 0.006
  34. Wnt-ß-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression. Nat Immunol. 2021 04; 22(4):471-484.
    View in: PubMed
    Score: 0.006
  35. Germline genetic contribution to the immune landscape of cancer. Immunity. 2021 02 09; 54(2):367-386.e8.
    View in: PubMed
    Score: 0.006
  36. Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. Hum Pathol. 2020 12; 106:54-61.
    View in: PubMed
    Score: 0.006
  37. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol. 2019 12 01; 5(12):1790-1798.
    View in: PubMed
    Score: 0.006
  38. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 05 22; 7(1):131.
    View in: PubMed
    Score: 0.005
  39. WNT/ß-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019 May 15; 25(10):3074-3083.
    View in: PubMed
    Score: 0.005
  40. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18.
    View in: PubMed
    Score: 0.005
  41. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res. 2018 09; 6(9):990-1000.
    View in: PubMed
    Score: 0.005
  42. Do clinicians know which of their patients have central venous catheters?: a multicenter observational study. Ann Intern Med. 2014 Oct 21; 161(8):562-7.
    View in: PubMed
    Score: 0.004
  43. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One. 2012; 7(10):e46104.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.